<DOC>
	<DOC>NCT02155322</DOC>
	<brief_summary>This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.</brief_summary>
	<brief_title>A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Competent to selfadminister the subcutaneous injections of PEGIFN Histologically documented involved regional lymph nodes of a primary cutaneous melanoma or unknown primary, meeting the study's staging criteria Had the primary melanoma completely resected with adequate surgical margins and undergone operation for positive regional lymph nodes within 84 days of study start Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 Adequate hepatic, renal and bone marrow function as defined by study parameters obtained within 4 weeks prior to study start For a female subject who is of childbearing potential or male participant with female sexual partner who is of childbearing potential, agree to use acceptable methods of contraception for at least 2 weeks prior to study start and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations Mucous membrane melanoma or ocular melanoma Known hypersensitivity to the components of study drug (including acetaminophen), or its analogs Evidence of distant or nonregional lymph node metastases or intransit metastases Disease that cannot be completely surgically resected Prior malignancy within the past 5 years other than surgically cured nonmelanoma skin cancer or cervical carcinoma in situ Severe cardiovascular disease, i.e. arrhythmias, requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease Hepatic decompensation Thyroid dysfunction not responsive to therapy Uncontrolled diabetes mellitus Clinically active autoimmune disease Clinically active and/or uncontrolled infection, including active hepatitis Human immunodeficiency virus (HIV) History of neuropsychiatric disorder requiring hospitalization Actively abusing alcohol or drugs Pregnant, lactating, or of reproductive potential and not using an effective means of contraception Medical condition requiring chronic systemic corticosteroids Received any experimental therapy within 30 days prior to enrolling in this study Received any prior chemotherapy, immunotherapy, hormonal or radiation therapy for melanoma Previously received interferonÎ± for any reason Known serious hypersensitivity reaction to PEGIFN or interferon alfa2b</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>